Skip to main content
Premium Trial:

Request an Annual Quote

Wyeth, Agilent Technologies

Wyeth has received US Patent No. 7,371,207, “Estrogen receptor α-regulated gene expression, related assays and therapeutics.” The patent describes a plurality of genes that demonstrate certain patterns of expression differing qualitatively or quantitatively, with and without exposure to estrogen and/or other hormone compositions. Methods of using these genes in identifying candidate agents that exert at least some of the biological effects of estrogen and/or other hormone, and pharmaceuticals and related therapies also is described. The use of the genes in methods of monitoring by use of nucleotide arrays or nucleotide filters is also provided.

Agilent Technologies has received US Patent No. 7,371,348, “Multiple array format.” The patent claims a multiple-array substrate having multiple assay chambers where each assay chamber contains one or more arrays. The assay chambers include a form-in-place gasket between a substrate and a cover. Methods of forming such multiple array substrates are also described. The assay chambers may further be associated with an analysis site for analyzing a sample solution contained within the assay chamber. Each assay chamber is in fluid communication with a port, and the ports are positioned in a spatial format adapted to interface to standard laboratory equipment for handling multiple fluids in parallel, the patent states.

Agilent has also received US Patent No. 7,371,519, “Methods and kits for indirect labeling of nucleic acids.” The patent claims methods and kits for labeling nucleic acids. According to the method, an oligonucleotide-tagged nucleic acid comprising an oligonucleotide tag is first generated. The oligonucleotide-tagged nucleic acid is then contacted under hybridization conditions with a labeled oligonucleotide complementary to the oligonucleotide tag, yielding a labeled nucleic acid. Kits for use in the method include a primer for use in enzymatically generating an oligonucleotide-tagged target nucleic acid, where the primer generally at least includes an oligo dT region and the oligonucleotide tag, and a labeled oligonucleotide complementary to the oligonucleotide tag. The methods and kits are particularly suited for use in gene expression analysis

Agilent has also received US Patent No. 7,372,982, “User interface for molecular array feature analysis.” The patent claims a method to allow an analyst or other user of molecular-array data to directly tailor pixel-intensity integration of scanned pixel-based representations of features of a molecular array to produce feature signals. The method is embodied in a graphical user interface that allows an analyst or other molecular-array user to input pixel-intensity-weighting functions into a computational system that applies the weighting functions prior to producing integrated feature signals, according to the patent’s abstract. The interface provides users with the ability to select the origin of a feature-centric rectilinear coordinate system and to input a function that specifies the function that is applied to the raw pixel intensities within the region of interest prior to integration of the pixel intensities within the region of interest to produce a feature signal.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.